Ignite Creation Date:
2024-05-06 @ 1:04 PM
Last Modification Date:
2024-10-26 @ 1:08 PM
Study NCT ID:
NCT03927274
Status:
TERMINATED
Last Update Posted:
2023-05-25
First Post:
2019-04-23
Brief Title:
Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III IV Glioma
Sponsor:
H Lee Moffitt Cancer Center and Research Institute
Organization:
H Lee Moffitt Cancer Center and Research Institute
Study Overview
Official Title:
A Study of Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery CED in Patients With Suspected RecurrentProgressive World Health Organization WHO Grade III or IV High Grade Glioma Undergoing Stereotactic Biopsy
Status:
TERMINATED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding unavailable
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine if treatment with Topotecan by an alternative method delivering topotecan directly into brain tumors is safe and well tolerated
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None